Literature DB >> 25307010

Acute coronary syndromes: treatment and risk stratification.

Antonio Eduardo Pereira Pesaro1, Paulo Cesar Gobert Damasceno Campos1, Marcelo Katz1, Thiago Domingos Corrêa1, Elias Knobel1.   

Abstract

BACKGROUND AND OBJECTIVES: Acute coronary syndromes result from a disruption of a vulnerable coronary plaque complicated by intraluminal thrombus formation, embolisation, and variable degrees of coronary obstruction. Patients with total occlusion may present with acute ST Elevation Myocardial Infarction (STEMI). Partial vessel obstruction may result in Non-ST-Elevation Acute Myocardial Infarction (NSTEMI) or unstable angina (UA). Clinical symptoms and electrocardiographic changes are the main components of identification of ACS. The rapid and effective triage of such patients regarding presence or absence of ST-segment elevation is critical to dictate further therapeutic strategies. The objective of this chapter was to review current evidence and recommendations for the evaluation and early treatment of acute coronary syndromes. CONTENTS: We performed a clinical review using the electronic databases MedLine and LILACS from January 1990 to September 2007.
CONCLUSIONS: Reperfusion of the infarct-related artery is the cornerstone of therapy for STEMI. Fibrinolysis and percutaneous coronary intervention are both well established as effective options. Management of UA/NSTEMI patients requires early risk stratification. High-risk patients should undergo an early invasive strategy that consists in performance of cardiac catheterization in the first 24 to 48 hours of presentation.

Entities:  

Year:  2008        PMID: 25307010

Source DB:  PubMed          Journal:  Rev Bras Ter Intensiva        ISSN: 0103-507X


  1 in total

1.  Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System.

Authors:  Vanessa Teich; Tony Piha; Lucas Fahham; Haline Bianca Squiassi; Everton de Matos Paloni; Paulo Miranda; Denizar Vianna Araújo
Journal:  Arq Bras Cardiol       Date:  2015-10       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.